President Donald Trump has signed an executive order directing the FDA to accelerate the review process for certain psychedelic therapies that have already received Breakthrough Therapy designation. The initiative aims to expand access to innovative treatments, particularly for veterans struggling with conditions such as PTSD, depression, and other mental health challenges. Supporters believe the move could help bring promising therapies to patients more quickly while maintaining regulatory oversight. The order marks a significant step in the ongoing national discussion about the medical use of psychedelic-assisted treatments.